{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:50:00Z","timestamp":1783713000720,"version":"3.55.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T00:00:00Z","timestamp":1595116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,2]]},"abstract":"\n Background:<\/jats:title>\n There are limited data regarding the incidence of adverse events associated with administering lacosamide by intravenous push (IVP) compared with IV piggyback (IVPB).<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n The objective of this analysis was to compare the safety profile, including cardiovascular effects, sedative effects, and IV site reactions of IVP and IVPB lacosamide administration.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n A retrospective pre\/post cohort analysis comparing patients who received lacosamide via IVP and IVPB was conducted. Safety end points included hypotension, bradycardia, medication-related sedation, and IV site reactions. The relationship between patient characteristics and the incidence of safety end points was analyzed using the Student t-test and \u03c7\n 2<\/jats:sup>\n test as appropriate.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Bradycardia occurred after 0.19% of IVP administrations and 1.09% of IVPB administrations assessed ( P = 0.07). Hypotension was observed in 3.16% of IVP administrations compared to 1.59% in the IVPB cohort ( P = 0.12). Post lacosamide-related sedation was noted in 11.32% and 11.68% of the IVP and IVPB cohorts, respectively ( P = 0.87). Infusion site reaction rates of 1.80% and 0.84% were documented in the IVP and IVPB cohorts, respectively ( P = 0.33). Of note, only 1 adverse event required clinical intervention. One 200-mg dose in the IVP cohort required a fluid bolus postadministration.<\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance:<\/jats:title>\n IVP lacosamide was associated with a similar incidence of cardiovascular, neurological, and infusion site\u2013related adverse events compared with IVPB, in which nearly every adverse event was deemed clinically insignificant. Lacosamide administered via IVP may be considered a safe alternative method of administration in the acute care setting.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/1060028020943569","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T01:53:28Z","timestamp":1595210008000},"page":"181-186","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Safety of Intravenous Push Lacosamide Compared With Intravenous Piggyback at a Tertiary Academic Medical Center"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3259-3547","authenticated-orcid":false,"given":"Kevin","family":"McLaughlin","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Carabetta","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s HealthCare, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hunt","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Schuler","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Ting","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7047-7512","authenticated-orcid":false,"given":"Lena K.","family":"Tran","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Szumita","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin E.","family":"Anger","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,7,19]]},"reference":[{"key":"bibr1-1060028020943569","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-018-0560-6"},{"key":"bibr2-1060028020943569","unstructured":"American Society of Health-System Pharmacists. Drug shortages resource center. Accessed August 15, 2019. https:\/\/www.ashp.org\/Drug-Shortages\/Current-Shortages\/"},{"key":"bibr3-1060028020943569","unstructured":"American Society of Health-System Pharmacists. Small-volume parenteral solutions shortages. Accessed August 15, 2019. https:\/\/www.ashp.org\/Drug-Shortages\/Shortage-Resources\/Publications\/Small-Volume-Parenteral-Solutions-Shortages"},{"key":"bibr4-1060028020943569","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.22.2983"},{"key":"bibr5-1060028020943569","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(74)91639-0"},{"key":"bibr6-1060028020943569","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAN.0000292567.17022.53"},{"key":"bibr7-1060028020943569","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr8-1060028020943569","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12058"},{"key":"bibr9-1060028020943569","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2012.05.005"},{"key":"bibr10-1060028020943569","unstructured":"VIMPAT\u00ae. Package insert. UCB Inc; 2017."},{"key":"bibr11-1060028020943569","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0276-0"},{"key":"bibr12-1060028020943569","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02463.x"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020943569","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020943569","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020943569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:45Z","timestamp":1777374945000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020943569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,19]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1177\/1060028020943569"],"URL":"https:\/\/doi.org\/10.1177\/1060028020943569","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,19]]}}}